Connect with us
European Gaming Congress 2024

Artificial Intelligence

Acute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies – Chimerix, GlycoMimetics, Arog, Delta-Fly, Jasper, Jazz, Daiichi Sankyo, Amgen, AbbVie, Merck, Eli Lilly

Published

on

New York, USA, Aug. 07, 2023 (GLOBE NEWSWIRE) — Acute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies – Chimerix, GlycoMimetics, Arog, Delta-Fly, Jasper, Jazz, Daiichi Sankyo, Amgen, AbbVie, Merck, Eli Lilly

The acute myeloid leukemia market has a promising outlook with emerging therapies. The overall dynamics of the acute myeloid leukemia market are anticipated to change in the coming years owing to the expected launch of Targeted therapies.

DelveInsight’s Acute Myeloid Leukemia Market Insights report includes a comprehensive understanding of current treatment practices, acute myeloid leukemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Acute Myeloid Leukemia Market Report

  • As per DelveInsight’s analysis, the acute myeloid leukemia market is anticipated to grow at a significant CAGR by 2032.
  • As per the DelveInsight estimates, in 2022, the total incident cases of AML were ~42K in the 7MM, which might reach ~48K cases by 2032. In the 7MM, the highest number of incident cases of AML was observed in the US. 
  • Leading acute myeloid leukemia companies such as CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, Polaris Group, Bio-Path Holdings, Inc., Chordia Therapeutics, Inc., Theradex, BioTheryX, Inc., Precigen, Inc, Eli Lilly and Company, Bayer, Takeda, Meryx, Inc., 2seventy bio, JW Pharmaceutical, Telios Pharma, Inc., Kartos Therapeutics, Inc., Celyad Oncology SA, Merck Sharp & Dohme LLC, Celgene, AbbVie, Genentech, Wugen, Inc., Arcellx, Inc, NextCure, Inc., Bellicum Pharmaceuticals, ImmunoGen, Inc., Astellas Pharma Inc, Aptose Biosciences Inc, Ascentage Pharma Group Inc., BioSight Ltd., GlycoMimetics Incorporated, Gilead Sciences, Chimerix, Daiichi Sankyo, Ryvu Therapeutics SA, Syros Pharmaceuticals, PrECOG, LLC, Cleave Therapeutics, Inc., Kronos Bio, Cullinan Oncology, LLC, Actinium Pharmaceuticals, Amgen, In8bio Inc, Sellas Life Sciences Group, Kura Oncology, Inc., Arog Pharmaceuticals, Inc., Novo Nordisk A/S, Marker Therapeutics, Inc., Shattuck Labs, Inc., Oncoceutics, Inc., and others are developing novel acute myeloid leukemia drugs that can be available in the acute myeloid leukemia market in the coming years.
  • Some of the key therapies for acute myeloid leukemia treatment include Fosciclopirox + Cytarabine, CPX-351, Minnelide, SNDX-5613, ASTX727, KPT-9274, SAR445419, ADI-PEG 20, BP1002, CTX-712, BTX-A51, PRGN-3006 T Cells, LY3214996, Regorafenib, GDX012, MRX-2843, SC-DARIC33, CWP232291, TL-895, KRT-232, CYAD-02, MK-0482, and others. 

Discover which therapies are expected to grab the major acute myeloid leukemia market share @ Acute Myeloid Leukemia Market Report

Acute Myeloid Leukemia Overview

Advertisement
Stake.com

Acute Myeloid Leukemia (AML) is a type of aggressive cancer that affects the bone marrow and blood. It primarily affects myeloid cells, which are responsible for producing red blood cells, platelets, and certain white blood cells. AML is characterized by the rapid proliferation of immature and abnormal myeloid cells, interfering with the production of healthy blood cells. The exact causes of AML are not always clear, but certain risk factors have been identified. 

The symptoms of AML often appear suddenly and can be quite severe. Common symptoms include unexplained fatigue, recurrent infections, easy bruising or bleeding, frequent nosebleeds, shortness of breath, and pale skin. AML can also lead to an enlarged spleen or liver, leading to discomfort in the abdomen. Diagnosing AML typically involves a series of tests, starting with a complete blood count to check for abnormal blood cell counts. Further tests, such as bone marrow aspiration and biopsy, are conducted to examine the bone marrow for abnormal cells and confirm the AML diagnosis.

Acute Myeloid Leukemia Epidemiology Segmentation

The acute myeloid leukemia epidemiology section provides insights into the historical and current acute myeloid leukemia patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The acute myeloid leukemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Advertisement
Stake.com
  • Total Acute Myeloid Leukemia Incident Cases 
  • Acute Myeloid Leukemia Gender-specific Cases 
  • Acute Myeloid Leukemia Age-specific Cases 
  • Acute Myeloid Leukemia Mutation-specific Cases 
  • Treated Cases of Acute Myeloid Leukemia by Line of Therapies

Download the report to understand which factors are driving acute myeloid leukemia epidemiology trends @ Acute Myeloid Leukemia Epidemiological Insights

Acute Myeloid Leukemia Treatment Market 

The treatment for AML typically involves a combination of therapies, tailored to each patient’s specific condition and health status. The primary goal of AML treatment is to achieve remission, where no cancer cells are detectable in the bone marrow. The main acute myeloid leukemia treatment approaches include chemotherapy, targeted therapy, and stem cell transplantation. Chemotherapy utilizes powerful drugs to destroy cancer cells, but it can also damage healthy cells, leading to side effects. Targeted therapy, on the other hand, aims to attack specific molecules or proteins involved in the growth of leukemia cells, reducing damage to normal cells. In some cases, stem cell transplantation may be recommended, particularly for patients with high-risk or relapsed AML. This procedure involves replacing damaged bone marrow with healthy stem cells from a compatible donor, either from a family member or an unrelated donor.

Advancements in research and personalized medicine have led to the development of novel treatments and therapies for AML. Clinical trials play a crucial role in evaluating new approaches and improving outcomes for patients. Multidisciplinary teams, including hematologists, oncologists, and other specialists, work closely together to provide comprehensive care, manage side effects, and support patients throughout their AML treatment journey. Early diagnosis and timely intervention remain essential factors in achieving successful outcomes for individuals facing this challenging disease.

To know more about acute myeloid leukemia treatment, visit @ Acute Myeloid Leukemia Treatment Drugs 

Key Acute Myeloid Leukemia Therapies and Companies

Advertisement
Stake.com
  • Fosciclopirox + Cytarabine: CicloMed LLC
  • CPX-351: Jazz Pharmaceuticals
  • Minnelide: Minneamrita Therapeutics LLC
  • SNDX-5613: Syndax Pharmaceuticals
  • ASTX727: Astex Pharmaceuticals, Inc.
  • KPT-9274: Karyopharm Therapeutics Inc
  • SAR445419: Sanofi
  • ADI-PEG 20: Polaris Group
  • BP1002: Bio-Path Holdings, Inc.
  • CTX-712: Chordia Therapeutics, Inc./Theradex
  • BTX-A51: BioTheryX, Inc.
  • PRGN-3006 T Cells: Precigen, Inc
  • LY3214996: Eli Lilly and Company
  • Regorafenib: Bayer
  • GDX012: Takeda
  • MRX-2843: Meryx, Inc.
  • SC-DARIC33: 2seventy bio
  • CWP232291: JW Pharmaceutical
  • TL-895: Telios Pharma, Inc.
  • KRT-232: Kartos Therapeutics, Inc.
  • CYAD-02: Celyad Oncology SA
  • MK-0482: Merck Sharp & Dohme LLC

Learn more about the FDA-approved drugs for acute myeloid leukemia @ Drugs for Acute Myeloid Leukemia Treatment 

Acute Myeloid Leukemia Market Dynamics

Acute myeloid leukemia was a rapidly evolving segment within the oncology market, and its dynamics were shaped by various factors. One key driver of the AML market was the rising global incidence of the disease, prompting increased demand for effective treatments. Pharmaceutical companies were heavily invested in research and development, focusing on novel therapies and targeted agents. The emergence of precision medicine and personalized treatment approaches allowed for more tailored and effective treatment options, leading to a shift from traditional chemotherapy to more innovative and potentially curative therapies.

In addition, the regulatory landscape played a crucial role in shaping the AML market dynamics. Expedited approval pathways, such as Breakthrough Therapy Designation and Fast Track designation, facilitated the accelerated introduction of promising drugs to the acute myeloid leukemia market, benefiting patients by providing quicker access to new treatments.

However, challenges persisted in the AML market, particularly related to the high cost of innovative therapies and the limited accessibility to these treatments in certain regions. Efforts were being made to address these issues, such as healthcare reforms and collaborations between governments, healthcare providers, and pharmaceutical companies. Furthermore, ongoing research and clinical trials continued to shed light on the underlying biology of AML, leading to a better understanding of disease mechanisms and potential therapeutic targets. This knowledge expansion fueled the development of more precise and effective treatments, promising better outcomes for patients in the future.

Acute Myeloid Leukemia Report Metrics Details
Study Period 2019–2032
Acute Myeloid Leukemia Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Acute Myeloid Leukemia Companies CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, Polaris Group, Bio-Path Holdings, Inc., Chordia Therapeutics, Inc., Theradex, BioTheryX, Inc., Precigen, Inc, Eli Lilly and Company, Bayer, Takeda, Meryx, Inc., 2seventy bio, JW Pharmaceutical, Telios Pharma, Inc., Kartos Therapeutics, Inc., Celyad Oncology SA, Merck Sharp & Dohme LLC, Celgene, AbbVie, Genentech, Wugen, Inc., Arcellx, Inc, NextCure, Inc., Bellicum Pharmaceuticals, ImmunoGen, Inc., Astellas Pharma Inc, Aptose Biosciences Inc, Ascentage Pharma Group Inc., BioSight Ltd., GlycoMimetics Incorporated, Gilead Sciences, Chimerix, Daiichi Sankyo, Ryvu Therapeutics SA, Syros Pharmaceuticals, PrECOG, LLC, Cleave Therapeutics, Inc., Kronos Bio, Cullinan Oncology, LLC, Actinium Pharmaceuticals, Amgen, In8bio Inc, Sellas Life Sciences Group, Kura Oncology, Inc., Arog Pharmaceuticals, Inc., Novo Nordisk A/S, Marker Therapeutics, Inc., Shattuck Labs, Inc., Oncoceutics, Inc., and others
Key Acute Myeloid Leukemia Therapies Fosciclopirox + Cytarabine, CPX-351, Minnelide, SNDX-5613, ASTX727, KPT-9274, SAR445419, ADI-PEG 20, BP1002, CTX-712, BTX-A51, PRGN-3006 T Cells, LY3214996, Regorafenib, GDX012, MRX-2843, SC-DARIC33, CWP232291, TL-895, KRT-232, CYAD-02, MK-0482, and others

Scope of the Acute Myeloid Leukemia Market Report

Advertisement
Stake.com
  • Therapeutic Assessment: Acute Myeloid Leukemia current marketed and emerging therapies
  • Acute Myeloid Leukemia Market Dynamics: Attribute Analysis of Emerging Acute Myeloid Leukemia Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Acute Myeloid Leukemia Market Access and Reimbursement

Discover more about acute myeloid leukemia drugs in development @ Acute Myeloid Leukemia Clinical Trials

Table of Contents

1. Acute Myeloid Leukemia Market Key Insights
2. Acute Myeloid Leukemia Market Report Introduction
3. Acute Myeloid Leukemia Market Overview at a Glance
4. Acute Myeloid Leukemia Market Executive Summary
5. Disease Background and Overview
6. Acute Myeloid Leukemia Treatment and Management
7. Acute Myeloid Leukemia Epidemiology and Patient Population
8. Patient Journey
9. Acute Myeloid Leukemia Marketed Drugs
10. Acute Myeloid Leukemia Emerging Drugs
11. Seven Major Acute Myeloid Leukemia Market Analysis
12. Acute Myeloid Leukemia Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Related Reports

Acute Myeloid Leukemia Epidemiology Forecast

Acute Myeloid Leukemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted acute myeloid leukemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute Myeloid Leukemia Pipeline

Advertisement
Stake.com

Acute Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute myeloid leukemia companies, including Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus,  C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals,  Lyell Immunopharma, Telix Pharmaceuticals, among others.

Chronic Lymphocytic Leukemia Market

Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic lymphocytic leukemia companies, including Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, among others.

Chronic Myeloid Leukemia Market

Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic myeloid leukemia companies, including Salarius Pharmaceuticals, Jazz Pharmaceuticals and Pharmamar, Eli Lilly, Pfizer, Bioatla, Cellectar Biosciences, Sumitomo Pharma Oncology, Inhibrx, among others.

Advertisement
Stake.com

Chronic Lymphocytic Leukemia Pipeline

Chronic Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic lymphocytic leukemia companies, including Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, among others.

Chronic Myeloid Leukemia Pipeline

Chronic Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic myeloid leukemia companies, including Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company, among others.

Other Trending Reports

Advertisement
Stake.com

Digestive System Fistula Market | Dementia With Diabetes Market | Leber’s Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Warm Autoimmune Hemolytic Anemia Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

Advertisement
Stake.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter


Artificial Intelligence

CapitaLand Investment launches research paper on ‘Asia Pacific Data Centre Investment Strategies in the Age of Digitalisation’

Published

on

capitaland-investment-launches-research-paper-on-‘asia-pacific-data-centre-investment-strategies-in-the-age-of-digitalisation’

 Strong secular tailwinds drive investors’ interest in the region’s sector
SINGAPORE, July 5, 2024 /PRNewswire/ — CapitaLand Investment (CLI) has launched its latest research paper on investment strategies for Asia Pacific’s (APAC) data centre (DC) industry as part of its ‘Perspectives’ research series.  Leveraging insights from CLI’s expertise on the ground, the research paper highlights the demand drivers behind the rapid growth of DCs in the region and strategic investment considerations for investors. The paper also includes a case study on navigating India’s DC sector.

Ms Michelle Lee, CLI’s Managing Director, Private Funds (Data Centre), said: “Digitalisation is a global mega trend driving the growth of data centres. With the DC sector’s strong secular tailwinds, 97% of institutional investors plan to increase their capital allocation into the sector1, particularly in Asia Pacific. As DCs are more resilient, allocation to this asset class can be an integral part of investors’ portfolio diversification strategy.”
“CLI has accelerated our growth in the DC sector, adding 22 DCs since 2021. Today, we have 27 DCs with about US$4.5 billion assets under management and more than 800 megawatts (MW) in gross power across eight countries globally2.  CLI has vertically integrated DC capabilities spanning across design, development, sales, and operations. With DC domain capabilities, combined with our deep market knowledge, deal-sourcing and investment network in Asia, we are well-positioned to partner with investors to tap into the wealth of opportunities in the sector,” added Ms Lee.
APAC as a strong growth market
While cloud computing has been the primary driver for DC demand, the rise of artificial intelligence (AI) is now fuelling a more explosive growth. The revolution in the scale at which data is being used and managed is fundamentally a global phenomenon, but nowhere is it unfolding as rapidly as in APAC markets. On population per MW basis, APAC markets are underserved compared to regions such as EMEA and North America3.
APAC economies are not only growing faster, the region’s enormous population and swelling internet user base also cement its status as a highly attractive destination for DC investment. Its internet user base has grown seven-fold since 2005, compared to the growth of 1.9 times in the Americas and 1.8 times in Europe over the same period4. Going forward, APAC markets should continue to lead, as internet adoption further increases given the lower penetration rates in the region.
DC transactions in APAC rose about 2.4 times to approximately US$22 billion from 2019 to 2023, compared to the preceding five years, even as markets generally stagnated during the COVID-19 pandemic5.
While hyperscalers continue to drive DC demand, APAC colocation market is also expected to double in size to US$52 billion by 20266, becoming the world’s largest colocation DC market.
Key DC markets in APAC
Tokyo, Osaka, Seoul, Singapore and Sydney are key developed DC markets in APAC7. These markets have achieved scale and are important DC hubs in the region.
Beijing and Shanghai also show promise due to China’s large population, growing digital services sectors, strong government support, and robust long-term economic prospects. 
Increasing demand for DCs in India
Highlighting India as a hotspot for DC investment, Mr Sanjeev Dasgupta, CLI’s CEO for India, said: “India’s DC industry has seen increasing interest from institutional investors and has a long runway for further growth. India has the world’s second highest number of mobile subscribers and one of the fastest growing data consumption per user rates. The government’s digitalisation drive, data localisation regulation as well as the growth of cloud and AI will generate more demand for DC capacity. With CLI’s 30 years of experience in India, we have the capabilities and a deep understanding of the local market. We have a dedicated team of DC experts in India and are currently developing four DCs across the key markets of Mumbai, Bengaluru, Chennai and Hyderabad with a total gross power of 244 MW.”
The seven major cities in India – Mumbai, Bengaluru, Chennai, Hyderabad, Delhi NCR, Pune, and Kolkata – are the focal points for new DC development, offering strategic locations with proximity to key business centres. Mumbai stands out as the preeminent hub, hosting more than half of the country’s DC capacity8 with the other major cities mentioned developing strongly.
Opportunities and strategic considerations
Different DC models offer a spectrum of options for investors, catering to different preferences and risk appetites. However, the lack of stabilised DCs available for sale in APAC means the most promising opportunities for investors lie in developing new DCs – a strategy that can both satisfy new demand and yield higher returns.
Power availability has taken centre stage as a crucial determinant for DC locations. There is also a growing emphasis on sustainability. Increasingly, DC users and savvy operators are seeking to reduce their carbon footprints by being more energy-efficient and tapping renewable energy sources.
Investors should also be mindful of the geopolitical, regulatory and technological risks associated with DC investments. It is therefore crucial for investors to collaborate with DC partners who have a strong network, local expertise, and specialist domain knowledge.
To read the full research paper on DC investment strategies in APAC, visit: https://www.capitaland.com/global/en/about-capitaland/newsroom/Perspectives/2024/Apac_Data_Centre_Investment_Strategies_Age_of_Digitisation.html
Launched in 2022, Perspectives is CLI’s series of thematic and topical research reports aimed at providing proprietary insights on real asset investment trends and strategies, private equity developments, macroeconomy and markets. For more, visit:https://www.capitaland.com/en/investment/news-and-events/perspectives.html
[1] 2024 Global Data Centre Investor Sentiment Survey, CBRE.
[2] Includes data centres in operation and under development.
[3] The World Bank, United Nations, CBRE, CLI PERA Research, June 2024.
[4] ITU World Communication, CLI PERA Research, June 2024.
[5] MSCI, Real Capital Analytics, CLI PERA Research, June 2024.
[6] CBRE, CLI PERA Research, June 2024.
[7] CBRE, Cushman & Wakefield, DC Byte, CLI PERA Research, June 2024.
[8] Avendus, “DCs: Powering Digital India”, May 2023, DC Byte, CLI PERA Research, June 2024.
 
Logo – https://mma.prnewswire.com/media/2259522/CapitaLand_without_investment_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/capitaland-investment-launches-research-paper-on-asia-pacific-data-centre-investment-strategies-in-the-age-of-digitalisation-302189520.html

Continue Reading

Artificial Intelligence

Securden Recognized as a Market Leader in GigaOm Radar Report for Enterprise Password Management

Published

on

securden-recognized-as-a-market-leader-in-gigaom-radar-report-for-enterprise-password-management

Securden has become a leader and an outperformer with cutting-edge features, rapid market advancements, and consistent customer value.
WILMINGTON, Del., July 4, 2024 /PRNewswire/ — Securden, Inc., a leading provider of privileged access and identity security solutions, today announced that it has been recognized as a leader and outperformer in GigaOm Radar Report for Enterprise Password Management.

GigaOm rigorously evaluates vendors in various solution segments and produces Radar reports with valuable insights to assist enterprise decision-makers in evaluating and investing in solutions.
The GigaOm Radar 2024 on Enterprise Password Management examined 13 enterprise password management solutions. “Securden is positioned in the innovation quadrant. It offers a strong solution, and its approach is to take its customers on a journey to broader PAM, with password management simply one focus area. It scored well across all of the decision criteria we evaluated, placing it as a leader, and its execution of the emerging features and rate of progress in the market classify it as an Outperformer,” states the report.
Securden has earned top ratings in key evaluation criteria, including platform security, security auditing, PAM capabilities, ease of management, ease of use, and scalability.
“We are proud to be recognized as a market leader in Enterprise Password Management by GigaOm Radar,” said Bala Venkatramani, CEO of Securden, Inc. “Protecting various identities used by humans and machines is a top priority for IT teams. Our platform offers a comprehensive privileged identity security solution, witnessing rapid adoption by SMBs and Enterprises globally. With innovation at the core, we are committed to offering simplicity and affordability in cybersecurity. This recognition affirms our strong market presence and our focus on providing powerful capabilities to strengthen our customers’ security posture.”
Securden offers robust protection for the vault with controls like access hardening, resilient deployment, and strong data protection approaches. It offers insights into password usage, identifies poor practices, flags failure to follow password standards, issues breach warnings identifying compromised passwords, and more. These measures significantly help reduce password-related risks.
Streak of Recognition
EMA Research, a top industry analyst firm, recently published an impact brief recognizing the Securden Unified PAM MSP platform as a groundbreaking development in privileged access management for MSPs. “By eliminating the need for disparate PAM solutions and providing comprehensive functionality within a single package, Securden empowers MSPs to deliver robust, scalable, and secure PAM services to their clients with unparalleled efficiency and confidence,” states the impact brief.
About Securden
Securden provides leading privileged access governance and identity security solutions that uniquely combine critical security principles to prevent cyberattacks, malware propagation and insider exploitation. With products designed for security and scalability (Password Vault for Enterprises, Unified PAM, Endpoint Privilege Manager, and Unified PAM MSP), Securden is trusted by organizations worldwide, including large financial institutions, government agencies, healthcare organizations, educational institutions, IT service providers, MSPs, and manufacturing companies. For more information, visit https://www.securden.com.
Media ContactJames [email protected]
Logo – https://mma.prnewswire.com/media/2362812/securden_logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/securden-recognized-as-a-market-leader-in-gigaom-radar-report-for-enterprise-password-management-302189680.html

Continue Reading

Artificial Intelligence

Managed Security Services Market Forecast to Exceed USD 101.86 Billion by 2031 Due to Escalating Security Concerns | SkyQuest Technology

Published

on

managed-security-services-market-forecast-to-exceed-usd-101.86-billion-by-2031-due-to-escalating-security-concerns-|-skyquest-technology

WESTFORD, Mass., July 4, 2024 /PRNewswire/ — According to SkyQuest, the global Managed Security Services Market size was valued at USD 26.89 billion in 2022 and is poised to grow from USD 31.18 billion in 2023 to USD 101.86 billion by 2031, growing at a CAGR of 15.95% during the forecast period (2024-2031).

The global managed security services market has been growing rapidly, over the last couple of years, due to the increasing security threats or risks and increasing challenges in managing security over IT networks. It’s impossible to ignore the fact that small businesses face relentless cyberattacks, including malware, ransomware, advanced threats, advanced persistent threats, and data breaches, leading to remote and hybrid operations systems.
Download a detailed overview:
https://www.skyquestt.com/sample-request/managed-security-services-market
Managed Security Services Market Overview:
Report Coverage
Details
Market Revenue in 2023
USD 31.18 billion
Estimated Value by 2031
USD 101.86 billion
Growth Rate
Poised to grow at a CAGR of 15.95%
Forecast Period
2024–2031
Forecast Units
Value (USD Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
Service Type, Type, Organization Size, Security, Type and Industry Vertical
Geographies Covered
North America, Europe, Asia Pacific, and the Rest of the world
Report Highlights
Updated financial information / product portfolio of players
Key Market Opportunities
Surge in Demand for Managed Detection and Response (MDR) Service
Key Market Drivers
Cyber Threats are Growing Complex 
Segments covered in Managed Security Services Market are as follows:
Service TypeManaged IAM, managed vulnerability management, managed risk and compliance, managed detection and response, managed firewall, and managed SIEM and log management, othersTypeFully managed, co-managedOrganization SizeSmall and medium-sized enterprises, Large enterprisesSecurity TypeNetwork security, cloud security, endpoint security, application security, othersIndustry VerticalBFSI, government, healthcare & life sciences, telecommunications, IT and ITeS, Retail and eCommerce, energy and utilities, manufacturing, and other verticalsRequest Free Customization of this report:
https://www.skyquestt.com/speak-with-analyst/managed-security-services-market
Rapid Responders: Incident Response Services
Managed detection and response are the large segment in the managed security services market. Managed detection-response services provide continuous improvement, threat detection, and response capabilities critical to today’s enterprises facing sophisticated cyber threats. This segment is characterized by the increasing prevalence and importance of cyberattacks advanced threat detection and response strategies beyond traditional security measures. The ability of the MDR service to provide comprehensive analysis of security incidents and take corrective action quickly is essential to minimize potential damage and ensure business continuity.
Managed identity and access management is the fastest growing segment in the market. The rising growth in this sector is driven by the need for robust stakeholder solutions in an era of digital transformation and remote collaboration. The rise of cyber threats and increasing regulatory requirements for data security and privacy and the main drivers of this segment.
Data Guardians: Data Protection Services
The global market recognizes the dominant position of the entire service management segment. This dominance is largely due to the scope of this role, in which companies assume full responsibility for an organization’s security programs from security providers, especially those without in-house security expertise or resources. These roles cover a wide range of security measures, including threat identification, incident response, compliance management and continuous monitoring. Adoption rates are also driven by the increasing complexity of cyber threats, which require a strong, 24/7 monitored security measure that only specialized providers can provide further strengthening its position as the largest market share.
In addition to the dominance of fully managed services, the advanced management segment is growing the fastest in the global market. This increase is driven by hybrid security models that offer a collaborative approach between internal IT teams and external security providers.
View report summary and Table of Contents (TOC):
https://www.skyquestt.com/report/managed-security-services-market
Safeguarding Tomorrow’s Digital Frontiers
As businesses and organizations take on the cyber panorama in terms of severe, MSS vendors remain vigilant guards, the use of advanced era and professional insights. Managed Security Services (MSS) have emerged as the cornerstone of present-day cybersecurity strategies, presenting strong protection in opposition to threats in a more and more digital international.
Related Report:
Cyber Security Market
Network Security Market
Endpoint Security Market
Cloud Security Market
Application Security Market
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact:Mr. Jagraj SinghSkyquest Technology1 Apache Way,Westford,Massachusetts 01886USA (+1) 351-333-4748Email: [email protected] Our Website: https://www.skyquestt.com/
Logo: https://mma.prnewswire.com/media/2446095/SkyQuest_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/managed-security-services-market-forecast-to-exceed-usd-101-86-billion-by-2031-due-to-escalating-security-concerns–skyquest-technology-302189493.html

Continue Reading
Advertisement
Stake.com
Advertisement

Latest News

Trending